Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow MNC versus CD133+ cell versus placebo intramyocardial injection in anterior myocardial infarction
IRCT201612201031N20Phase 3Completed
- Sponsor
- Royan Institute
- Start
- Dec 2007
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3 trial of autologous bone marrow-derived mononuclear cell and autologous CD133+ bone marrow-derived stem cells in myocardial infarction (MI) (3 arms), sponsored by Royan Institute. Primary endpoint: Left ventricular ejection fraction. Started Dec 2007; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cellautologous CD133+ bone marrow-derived stem cells
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT201612201031N20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201612201031N20.